Public-registry site landscape for NCT02012920, a Castration-resistant Prostate Cancer study sponsored by Innocrin Pharmaceutical. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02012920 (registry record) |
| Sponsor | Innocrin Pharmaceutical |
| Condition(s) | Castration-resistant Prostate Cancer; CRPC |
| Phase | PHASE2 |
| Listed sites | 23 |
| Site countries | United States, Greece, Switzerland, United Kingdom |
Eichor generates a preliminary site-risk snapshot for NCT02012920 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →